Suppression of an excessive systemic inflammatory response is a promising and potent strategy for treating endotoxic sepsis. Indoleamine 2,3-dioxygenase (IDO), which is the rate-limiting enzyme for tryptophan catabolism, may play a critical role in various inflammatory disorders. In this study, we report a critical role for IDO in the dysregulated immune response associated with endotoxin shock. We found that IDO knockout (IDO ؊/؊ ) mice and 1-methyl-D-tryptophan-treated, endotoxin-shocked mice had decreased levels of the cytokines, TNF-␣, IL-6, and IL-12, and enhanced levels of IL-10. Blockade of IDO is thought to promote host survival in LPS-induced endotoxin shock, yet little is known about the molecular mechanisms that regulate IDO expression during endotoxin shock. In vitro and in vivo, IDO expression was increased by exogenous IL-12, but decreased by exogenous IL-10 in dendritic cells and splenic dendritic cells. Interestingly, whereas LPS-induced IL-12 levels in serum were higher than those of IL-10, the balance between serum IL-12 and IL-10 following challenge became reversed in IDO 
S
epsis is a systemic inflammatory response syndrome induced by microbial infection that is characterized by hemodynamic shock and multiple organ failure (1, 2) . The pathogenesis of sepsis involves a progressive and dynamic expansion of a systemic inflammatory response to bacterial infection (3) . Endotoxin, or LPS, is a major component of the outer membrane of Gram-negative bacteria; as such, it is an effective trigger of the inflammatory response during infection with Gram-negative bacteria. Uncontrolled activation of LPS-induced mechanisms results in sepsis. However, growing evidence supports the idea that LPS does not directly cause septic shock and tissue injury. Rather, it stimulates the production of proinflammatory cytokines, such as TNF-␣ and IL-1␤, which, in the context of massive infections associated with sepsis, can precipitate tissue injury and lethal shock (1, 4) . It is a major cause of morbidity and mortality in hospitalized patients, yet effective treatment modalities remain elusive. Sepsis is associated with acute and systemic host immune responses; in the case of cell-mediated immune responses, the release of cytokines, such as TNF-␣, IL-1␤, IL-6, IL-12p70, and IFN-␥, is mechanistically involved in sepsis development (5) . Immune and inflammatory systems are controlled by multiple proand anti-inflammatory cytokines, many of which are absent under normal, homeostatic conditions. However, massive bacterial infections cause the host to produce excessive amounts of proinflammatory cytokines that threaten the host's survival (6) . Thus, the balance between proinflammatory and anti-inflammatory influences is likely a critical element in the mechanism of sepsis.
Dendritic cells (DCs) 3 are potent APCs and provide costimulatory signals for innate and adaptive immune responses. For example, LPS promotes DC maturation and IL-12 secretion, which primes naive CD4 T cell toward a Th1 phenotype (7) . In contrast, IL-10 production by DCs promotes development of a Th2 phenotype in an autocrine manner by inhibiting IL-12 production (8) . Impaired immune function and associated immunosuppression are hallmarks of existing therapies used to treat sepsis. In sepsis, the balance between pro-and anti-inflammatory cytokines might be even more important in DCs than in other immune cells. This is because severe sepsis results in alterations in IL-12 and IL-10 production by DCs (9) , and the tolerogenic DC subsets that produce IL-10 suppress LPS-induced, acute lethal systemic inflammatory responses (10) . For these reasons, a keener understanding of the balance between IL-12 and IL-10 in DCs should provide insight into the pathophysiology of sepsis.
Indoleamine 2,3-dioxygenase (IDO), which is the rate-limiting enzyme for tryptophan catabolism, is inducibly expressed in DCs in response to LPS and IFN stimulation (11) . IDO in tissue has long been known to play a role in the immune tolerance of transplants and tumors, but the role of IDO induction in DCs has only recently begun to be explored. A recent study using IDO knockout (IDO Ϫ/Ϫ ) mice revealed that IDO in lung DCs promoted Th2-mediated allergic airway inflammation, but was not essential for immune tolerance via inhibition of Th1 response (12) . In a collagen-induced arthritis model, IDO-expressing DCs were shown to be involved in down-regulating Th1 cytokine production (13) . Recently, IDO has been reported to play a key role in controlling the flux between pathways that lead to pro-and anti-inflammatory cytokine production in DCs (14) . Despite the apparent centrality of IDO-expressing DCs in the pathophysiology of sepsis, the mechanism of action of DCs in sepsis remains elusive. In this study, we examined the function of IDO expressed in bone marrow-derived DCs (BMDCs) in a mouse LPS-induced endotoxin shock model, focusing specifically on whether blocking or knocking out IDO reduced the lethality of endotoxin shock by reducing the production of proinflammatory cytokines in DCs.
Materials and Methods

Mice and Materials
Male 6-to 8-wk-old C57BL/6 (H-2K b and I-A b ) mice were purchased from the Korean Institute of Chemistry Technology. Indo Ϫ/Ϫ C57BL/6 mice were obtained from The Jackson Laboratory. Mice that were wild-type (WT) (ϩ/ϩ) or homozygous null (Ϫ/Ϫ) for targeted disruption of the IDO gene were selected from offspring of heterozygous/homozygous mating by PCR tail DNA. Age-matched WT (ϩ/ϩ) littermates were used as controls. They were housed in a specific pathogen-free environment within our animal facility for at least 1 wk before use. All experiments were done in accordance with the guidelines of the committee of Ethics of Animal Experiments, Pusan National University. LPS from Escherichia coli (serotype 055:B5) was obtained from Sigma-Aldrich. Recombinant mouse (rm)GM-CSF and rmIL-4 were obtained from R&D Systems. rIL-12 p70 and IL-10 were obtained from PeproTech. Abs of rat IgG, anti-mouse IL-12, and anti-mouse IL-10 were obtained from R&D Systems. Anti-IDO was obtained from Alexis. Anti-␣-tubulin was obtained from Santa Cruz Biotechnology. The 1-methyl-D-tryptophan (1-MT) was obtained from Sigma-Aldrich.
Generation and culture of DCs
DCs were generated from murine bone marrow monocyte cells, according to the procedure of Inaba et al. (15) , with minor modification. Briefly, bone marrow was flushed from the tibiae and femurs of 6-to 8-wk male C57BL/6 and depleted of RBC with RBC lysing buffer (Sigma-Aldrich). The cells were plated in 6-well culture plates (1 ϫ 10 6 cells/ml; 2 ml/well) in RPMI 1640 supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 20 ng/ml rmGM-CSF, and 10 ng/ml rmIL-4 at 37°C in 5% CO 2 . On days 3 and 5 of the culture, floating cells were gently removed and fresh medium was added. On day 6 of the culture, nonadherent cells and loosely adherent proliferating DC aggregates were harvested for analysis or stimulation. On day 7, 80% or more of the nonadherent cells expressed CD11c.
LPS injection and mouse model of endotoxin shock
The mice (20 -25 g ) were injected i.p. with saline or LPS (20 mg/kg), dissolved in saline. The 1-MT (10 mg ml Ϫ1 mouse Ϫ1 ) was i.p. injected for 12 h before LPS administration. The 1-MT dose was chosen in agreement with previously reported observations (16) . The mortality of mice was monitored for 6 days. The plasma was collected 1 and 4 h after LPS (20 mg/kg) injection. For intracellular IDO expression in splenic DCs, their spleens were disrupted, the cells were centrifuged at 400 ϫ g for 5 min, and RBC were removed from mouse splenocytes by treatment of RBC lysing buffer (Sigma-Aldrich). Then the cells were harvested and washed twice with PBS containing 2% FBS and 0.1% sodium azide.
In vivo treatment with rIL-12 and rIL-10, or neutralizing anti-IL-12 and anti-IL-10 Abs
To verify the role of the cytokines, IL-12 and IL-10, in LPS-induced IDO expression in mice, we injected mice i.v. with rmIL-12 or rmIL-10 (1 g/mouse) or an equal volume of PBS 24 h before LPS injection (20 mg/kg, i.p.). Mice were also treated with neutralizing Abs (500 ng/mouse), diluted in sterile enodotoxin-free PBS and delivered by i.v. injection 24 h before LPS injection (20 mg/kg, i.p.). Control mice were injected i.v. with an equal dose of rat IgG1 (isotype Ab control) or PBS (vehicle control). Mice were evaluated 24 h after treating with LPS.
Western blot analysis
DCs were washed twice with TBS and lysed by the addition of ice-cold lysis buffer, containing 0.5% Triton X-100, 50 mM Tris (pH 8.0), 150 mM NaCl, 5 mM EDTA, 5 mM NaF, 1 mM Na 3 VO 4 , 10 g/ml aprotinin, pepstatin A, and 5 g/ml leupeptin. Lysates were left on ice for 20 min and centrifuged for 30 min at 12,000 ϫ g in a microcentrifuge at 4°C to remove nuclei. Proteins were separated on 12% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% nonfat dried milk in T-PBS (0.2% Tween 20 in PBS) and incubated with Ab against IDO or ␣-tubulin Ab to detect the loading amount. Membranes were subsequently washed and incubated for 1 h with secondary Ab conjugated to HRP. Immunolabeling was detected using an ECL detection system (Millipore).
Cytokine quantification
Cytokines contained in plasma and supernatants from the cell culture were analyzed for TNF-␣, IL-6, IL-12 p70, and IL-10 content in triplicate using an ELISA kit obtained from R&D Systems.
Confocal microscopy
Mice were injected with PBS and LPS (20 mg/kg) challenge for 24 h, and then spleen was taken out. Localization of IDO was determined by using rabbit anti-mouse IDO Abs, followed by incubation with FITC-labeled anti-rabbit IgG. Localization of DC was determined by using PE-labeled anti-mouse CD11c. Spleen was examined by confocal fluorescence microscopy (Zeiss LSM 510) with a ϫ40 oil immersion objective.
Flow cytometry
Intracellular IDO expression in splenic CD11c
ϩ DCs was assayed by flow cytometry, as previously reported (17) . In brief, 6-wk-old, male C57BL/6 mice were injected i.p. with LPS. Spleens were disrupted and RBC was isolated from splenocytes by treatment with a red cell lysis buffer (SigmaAldrich). Cells were then harvested and washed twice with PBS containing with 2% FBS and 0.1% sodium azide. For intracellular IDO staining, we used a BD Cytofix/Cytoperm kit (BD Pharmingen), following the manufacturer's instructions. Intracellular IDO protein was detected with a rabbit anti-mouse IDO primary Ab (Alexis) and a FITC-conjugated goat antirabbit IgG secondary Ab (Chemicon International). Surface molecules were analyzed by staining cells with PE-conjugated anti-CD11c. The stained cells (10 5 CD11c ϩ cells) were analyzed using a FACSCalibur flow cytometry system (BD Biosciences).
Statistical analysis
Experiments were repeated at least three times with consistent results. Unless otherwise stated, data are expressed as the mean Ϯ SEM. ANOVA was used to compare experimental groups to control values. Comparisons between multiple groups were done using Tukey's multiple comparison test. Statistical significance was determined as p value less than 0.05. KaplanMeier curves were analyzed using a log rank test.
Results
IDO Ϫ/Ϫ mice are resistant to LPS-induced endotoxin shock
To investigate the role of IDO in endotoxin shock, we evaluated survival after LPS-induced endotoxin shock in IDO knockout (IDO Ϫ/Ϫ ) and WT mice. The survival of IDO Ϫ/Ϫ mice was 70% at 48 h after i.p. injection of 20 mg/kg LPS, whereas the survival of WT mice was 30% (Fig. 1A, upper panel) . To confirm this apparent survival benefit of IDO deficiency without the potential confounding effects of long-term compensation in the knockout mouse system, we tested the specific IDO activity inhibitor, 1-MT, in the LPS-induced endotoxin shock model (Fig. 1A, lower panel) . Consistent with the results obtained with IDO Ϫ/Ϫ mice, survival at 48 h after LPS-induced endotoxin shock was significantly increased (to 60%) by treatment with 1-MT before LPS challenge compared with that in controls receiving PBS treatment (30%). In addition, more than 20% of IDO Ϫ/Ϫ -and 1-MT-treated mice survived beyond 6 days after LPS challenge. This result is in sharp contrast to those obtained with WT or PBS-treated mice, which all died within 80 h after LPS challenge, and clearly demonstrates the positive effect of inhibiting IDO on postendotoxic shock survival.
TNF-␣ and IL-6 are important proinflammatory cytokines in sepsis pathophysiology, and have been shown to lead to septic shock (5). After LPS challenge in IDO Ϫ/Ϫ mice, the serum levels of TNF-␣ and IL-6, 1.13 Ϯ 0.02 ng/ml and 1.14 Ϯ 0.05 ng/ml, respectively, were markedly lower than the corresponding values of 2.12 Ϯ 0.04 ng/ml and 3.20 Ϯ 0.04 ng/ml after LPS challenge in WT mice (Fig. 1B) . Consistent with this observation, the serum levels of TNF-␣ (1.99 Ϯ 0.12 ng/ml) and IL-6 (2.92 Ϯ 0.14 ng/ml) in WT mice were significantly reduced by pretreatment with 1-MT to 0.07 Ϯ 0.07 ng/ml and 1.45 Ϯ 0.45 ng/ml, respectively (Fig.  1C) . These cytokines were undetectable in serum of mice treated with PBS instead of LPS. These in vivo results indicate that reducing IDO expression or activity might have therapeutic potential to promote survival in endotoxin shock by suppressing proinflammatory cytokine production.
DCs increases the expression of IDO during endotoxin shock
To determine whether IDO-expressing DCs were altered in mice during endotoxin shock, we investigated the population of DCs in the white pulp T cell zone in the spleen. In the normal mouse spleen, two subpopulations of DCs have been demonstrated to exist in anatomically distinct locations (18) . Whereas a major population of marginal DCs is located between red and white pulp in spleen, a minor population of so-called interdigitating DCs is located in the white pulp T cell zone (18) . The administration of LPS in mice has been shown to cause marginal DCs to mature and migrate into the white pulp T cell areas, and then migrate out as interdigitating DCs (19) . Strikingly, although the total number of CD11c ϩ DCs was reduced in mice challenged with LPS for 24 h (data not shown), the number of interdigitating DCs was significantly increased; importantly, these latter cells also expressed IDO (Fig. 2A) . Furthermore, to verify that LPS-activated DCs migrated into the white pulp T cell areas of the spleen as interdigitating DCs, we stained spleens with CD11c-PE and CD3-FITC Abs (Supplemental Fig. 1) . 4 In the spleens of LPS-injected mice, some of the marginal DCs had migrated into the white pulp T cell areas. In addition, the level of IDO expression in CD11c ϩ DCs in the spleen was increased after LPS challenge in a dose-and timedependent manner (Fig. 2, B and C) . Furthermore, the level of IDO expression in BMDCs increased in vitro in a dose-and time-dependent manner when stimulated with LPS (Fig. 2, D and E).
IL-12 increases, but IL-10 decreases IDO expression in BMDCs
To elucidate the cellular mechanism by which IDO in DCs regulates immunity, we measured production of the proinflammatory cytokine, IL-12, and anti-inflammatory cytokine, IL-10, in DCs. IL-12 is a central inducer of cell-mediated immunity, and excessive production of IL-12 may be involved in the pathogenesis of autoimmunity (20), whereas IL-10 inhibits the production of proinflammatory cytokines, such as IL-12, TNF-␣, and IFN-␥ (21). Reports have shown that exogenous IL-10 improves survival from sepsis after cecal ligation and puncture in mice by decreasing IL-6 and TNF-␣ (22), and postseptic mice exhibit a significant decrease in IL-12 and an increase in IL-10 production in pulmonary DCs (9) .
Interestingly, in the present study, we found that the production of both IL-12 and IL-10 was greatly elevated in BMDCs following stimulation with LPS, although the magnitude and rate of IL-12 production were greater than that of IL-10 (Fig. 3A) . Similarly, LPS challenge increased the serum levels of IL-12 and IL-10 in vivo (Fig. 3B) . These two cytokines are antagonistic in BMDCs; that is, IL-10 pretreatment for 2 h reduced LPS-induced IL-12 4 The online version of this article contains supplementary material. production and vice versa (Fig. 3C) . Furthermore, exogenous IL-12 stimulation increased IDO expression in BMDCs, and synergized with LPS to further increase IDO expression (Fig. 3D,  upper panel) . In contrast, LPS-induced IL-10 apparently exerts a negative regulatory effect on IDO production: exogenous IL-10 stimulation suppressed the IDO expression induced by LPS in BMDCs, although it had little effect on the constitutive expression of IDO (Fig. 3D, lower panel) . To confirm the effect of IL-12 and IL-10 on IDO expression in the spleen, we injected rmIL-12 or rmIL-10 (1 g/mouse, i.v.) into mice 24 h before LPS injection (20 mg/kg). IL-12 alone enhanced splenic IDO expression. In mice examined 24 h after LPS injection, IL-12 was found to synergize with LPS to further increase IDO expression in splenic DCs as well as BMDCs (Fig. 3E, upper  panel) . In contrast, IL-10 treatment diminished LPS-induced IDO expression (Fig. 3E, lower panel) . These data show that IDO expression may be regulated by IL-12 and IL-10 signaling in BMDCs and splenic DCs. 
Regulation of IL-12 and IL-10 balance modulates IDO expression in BMDCs
To ascertain whether the effects of LPS-induced secretion of IL-12 and IL-10 on IDO expression are via autocrine action in BMDCs, we treated cells with neutralizing Abs against IL-12 and IL-10 before LPS stimulation. As expected, the extracellular application of a neutralizing Ab against IL-12 significantly reduced LPS-induced IDO expression in BMDCs (Fig. 4A, upper panel) and in the splenic DCs (Fig. 4B, upper panel) . Surprisingly, pretreatment of BMDCs with an IL-10-neutralizing Ab, which we had expected would enhance IDO expression by up-regulating IL-12 production, had no effect on LPS-induced IL-12 production (data not shown) or IDO expression in BMDCs (Fig. 4A, lower panel) and in the splenic DCs (Fig. 4B, lower panel) . Next, we then determined whether altering the balance between IL-12 and IL-10 was able to regulate IDO expression. In these experiments, the IL-12 and IL-10 balance was manipulated by treating BMDCs with increasing doses of IL-10 in the presence of a constant amount of exogenous IL-12, and changes in IDO expression in BMDCs were measured. We found that the induction of IDO expression by IL-12 stimulation was significantly diminished as the concentration of exogenous IL-10 increased (Fig. 4C ). These results demonstrate that, although LPS stimulation of BMDCs increased both IL-12 (proinflammatory) and IL-10 (antiinflammatory) cytokines, the net effect on IDO expression in BMDCs depended on the balance of IL-12 and IL-10.
Blockade of IDO reverses the IL-12 and IL-10 balance by LPS in mice
We assessed whether inhibiting of IDO by IDO Ϫ/Ϫ and 1-MT administration into mice would affect the IL-12 and IL-10 balance by LPS. The balance between IL-12 and IL-10 levels was evaluated in vivo using the LPS-induced endotoxin shock model. The serum levels of IL-12 and IL-10 were measured 24 h after LPS-induced endotoxin shock in IDO Ϫ/Ϫ -and 1-MTtreated mice. Consistent with the in vitro results, we found that both IL-12 and IL-10 were significantly increased by LPS challenge relative to PBS treatment. In WT mice, the balance of IL-12 and IL-10 was skewed toward IL-12 (proinflammatory reaction). However, in IDO Ϫ/Ϫ mice, this balance was changed and was now skewed toward IL-10 (anti-inflammatory reaction); thus, both IL-12 and IL-10 were increased by LPS challenge, but IL-10 was increased much more than IL-12 (Fig. 5A) . The involvement of IDO in determining the IL-12 and IL-10 balance was confirmed in 1-MT-treated mice (Fig. 5B) . Taken together, these data suggest that whereas the production of both IL-12 and IL-10, which have opposing actions on IDO expression, was increased in DCs by LPS, their net effect in LPSinduced endotoxin shock resulted in increased IDO expression, which, in turn, positively regulated IL-12, although negatively regulated IL-10 in DCs. 
Discussion
To the best of our knowledge, this is the first report describing the effects of IDO on LPS-induced endotoxin shock. In a previous study, IDO, which is the rate-limiting enzyme for tryptophan catabolism, was shown to be part of the host defense mechanism against pathogens (23) . It is now clear that IDO serves more than one role in the immune system (24) . To date, in vivo studies of IDO have typically used injection of IDO-expressing cells and have focused on the immunosuppressive and tolerance-promoting effects of IDO. The physiological role of IDO in disease processes has been less well explored; in particular, it is not clear whether these roles are always beneficial to the host. Inhibition of IDO activity during immune-mediated colitis has recently been reported to markedly worsen disease in the gut (25) . In sharp contrast, IDO can act as a mediator of inflammatory disease, particularly in ischemia-reperfusion injury (26) . However, the effects of IDO function in LPS-induced endotoxin shock in mice remain unknown. In this study, we assessed the effect of IDO deficiency on the host inflammatory response to LPS-induced endotoxin shock and showed that survival from endotoxin shock was increased in IDO knockout mice compared with WT mice. Furthermore, proinflammatory cytokines that are important mediators of endotoxin shock, such as TNF-␣ and IL-6, also decreased in IDO-deficient mice, indicating that blockade of IDO is a potential therapeutic strategy for the treatment of endotoxic shock. Corticosteroids are well known for their potent anti-inflammatory properties, and it has been recently reported that treatment with dexamethasone, which is the corticosteroid most frequently used to reduce inflammatory reactions, typically increases the survival rate of mice to ϳ20% at 120 h after LPS-induced sepsis (27) . This result is comparable to that obtained by blocking IDO activity, suggesting that the inhibition of IDO might have anti-inflammatory effects that are similar to those of corticosteroids.
IDO is known as an inducible enzyme in some kinds of immune cells, including DCs, macrophages, and eosinophils, but IDO function in the immune system appears to diverge depending on the type of immune cell and of the nature of the stimulus. For example, the induction of IDO expression in plasmacytoid (CD123 ϩ ) DCs by IFN-␥ stimulation induced T cell tolerance through tryptophan catabolism in allograft transplantation (24) . But others have shown that the inhibition of IDO prevented ischemia-reperfusion, injuryinduced apoptosis of renal cells after renal transplantation in mice (26) . We performed additional experiments with DCs to evaluate the underlying mechanism of IDO function in sepsis pathophysiology for several reasons: 1) DCs are considered to play an important role in determining the establishment of immunity and tolerance (28, 29) . 2) Although their numbers are reduced during sepsis in mice and humans, DCs play a pivotal role in sepsis because their recruitment to areas of inflammation in response to chemotactic stimuli is necessary for an optimal immune response (30). 3) IDO is induced in DCs by IFNs or LPS stimulation. 4) DCs can prime Th cells to Th1 immune response and produce Th1 cytokines, including TNF-␣, IL-1␤, and IL-6, all of which are of key importance in sepsis pathophysiology. 5) As a potent APC type, DCs have an abundance of TLR-4, which might play an important role in sepsis development (31) . Despite these multiple lines of evidence, the understanding of DC biology, especially in sepsis, remains insufficient. Our data showed that, although the total number of CD11c ϩ DCs decreased during LPS-induced endotoxin shock, as others have shown (32) , the number of IDOexpressing interdigitating DCs increased.
In the present study, the proinflammatory cytokine, IL-12 p70, induced IDO expression even in the absence of LPS, and LPSinduced IDO expression was blocked in BMDCs pretreated with an IL-12-neutralizing Ab, indicating that IDO expression may be regulated by IL-12 production in an autocrine manner in LPSactivated BMDCs. In contrast, the anti-inflammatory cytokine, IL-10, reduced LPS-induced IDO expression via inhibition of IL-12 production. These findings provide new insight into the molecular mechanism by which LPS induces IDO expression in BMDCs, demonstrating that IL-12 and IL-10 are upstream modulators of IDO expression. This is consistent with the observation that the cytokines, IL-2, IL-4, IL-10, IL-12, and TGF-␤, modulate IDO expression in a manner that depends on the cell type and the cytokine milieu (33) (34) (35) (36) (37) (38) . Previous reports have shown that IL-10 inhibits the transcription of the p40 subunit of IL-12, which is essential for formation of the functional dimeric form of IL-12 (39) . Mouse IL-12 is a 70-kDa heterodimer composed of a p35 subunit, which cannot be secreted alone (40) , and a p40 subunit; neither subunit has IL-12 activity in a homodimeric form. In addition, the p40 homodimer, which can be secreted, binds to the IL-12R and acts as an IL-12 antagonist (41). Therefore, IL-10 would appear to repress IDO production in BMDCs through an indirect pathway, such as blocking the transcription of the p40 subunit of IL-12. Recent evidence suggests that the balance of proinflammatory cytokines (IFN-␥, IL-2, and IL-12), which support cellular aspects of immune functions, and anti-inflammatory cytokines (IL-4 and IL-10), which modulate the proinflammatory response, crucially regulates the immune response (42, 43) . It has also been reported that disruption of the pro-and antiinflammatory cytokine balance can lead to inflammation and tissue damage on the one hand or susceptibility to infection on the other (44) . However, an effect of cytokine balance, especially that of IL-12 and IL-10, on IDO expression in LPS-activated BMDCs has not previously been shown. Therefore, we also investigated the effect of IL-12 and IL-10 balance on IDO expression. IL-12-induced IDO expression in BMDCs was dramatically decreased as the concentration of exogenous IL-10 was increased, indicating that under conditions in which IL-12 predominates over IL-10, IDO expression in BMDCs increases, and vice versa.
On the basis of our in vitro and in vivo observation that alterations in the IL-12 and IL-10 balance regulate IDO expression, we wondered whether blockade of IDO has an effect on IL-12 and IL-10 balance in mice. It was demonstrated recently that LPS-induced IL-12 p70 production was significantly inhibited in BMDCs in the presence of 1-MT, a specific inhibitor of IDO activity in vitro (14) . Following i.p. injection of LPS, the serum level of IL-12 was decreased, but the serum level of IL-10 was increased in IDO Ϫ/Ϫ mice compared with WT mice. These results indicate that IDO expression can also affect the IL-12 and IL-10 balance in vivo. Hence, blocking or knocking out IDO decreased IL-12 levels, while increasing those of IL-10 in LPS-induced endotoxin shock, resulting in increased survival.
It has been reported that the functional importance of Toll receptors is emphasized by association of LPS hyporesponsiveness, whereas susceptibility to Gram-negative infections with immobilizing mutations in the TLR4 gene is demonstrated by a single point mutation in C3H/HeJ mice (45) and a deletion in C57BL/ 10ScCr mice (46) . Endotoxemia is simple to achieve experimentally, but imperfectly reproduces sepsis. Thus, whether the absence of IDO may have opposite effects in a true sepsis model needs further investigation in a murine sepsis model created using live bacteria or cecal ligation and puncture. In this study, we demonstrated that the factor that determines whether DCs promote immunity or tolerance is the IL-12 and IL-10 balance, which may be crucially regulated by IDO to modulate the consequences of severe sepsis (Fig. 6 ). In conclusion, the present evidence indicates that endotoxin-induced IDO expression may elicit a proinflammatory response in DCs and is, thus, detrimental in sepsis. These results suggest that IDO may regulate organismal inflammatory mechanisms and, as such, may be an effective target for treating systemic inflammatory response syndrome or sepsis induced by endotoxin.
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